---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-001049"
form_type: "8-K"
ticker: "ZEOX"
cik: "0001557376"
company_name: "Zeo ScientifiX, Inc."
filed_at: "2025-02-18T23:59:59+00:00"
generated_at: "2026-05-26T16:08:43.866088+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ZEO ScientifiX appoints Dr. Peter A.M. Everts as Chief Scientific and Technology Officer

## Summary
- Dr. Everts brings 35+ years of experience in orthobiology, spine, wound care, and regenerative medicine.
- Previously CSO at EmCyte Corp and co-founder of Da Vinci Clinic, Netherlands; holds Ph.D. from University of Utrecht.
- ZEO is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases.
- Interim CEO Ian Bothwell says appointment underscores commitment to accelerating innovation and expanding regenerative therapies.

## SEC filing metadata
- accession: 0001829126-25-001049
- form_type: 8-K
- ticker: ZEOX
- cik: 0001557376
- company_name: Zeo ScientifiX, Inc.
- filed_at: 2025-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/0001829126-25-001049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/zeoscientifix_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-001049
- JSON: https://secwatch.observer/filing/0001829126-25-001049.json
- Plain text: https://secwatch.observer/filing/0001829126-25-001049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.